Evidence mapPaperPMID 39459455Full record

ReviewMedicina (Kaunas, Lithuania)2024

Exploring Adiposity and Chronic Kidney Disease: Clinical Implications, Management Strategies, Prognostic Considerations.

Lasin Ozbek, Sama Mahmoud Abdel-Rahman, Selen Unlu, Mustafa Guldan, Sidar Copur, Alexandru Burlacu, Adrian Covic, Mehmet Kanbay

Abstract readReview
In one paragraph

Review in Medicina (Kaunas, Lithuania), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Osteosarcopenia in Chronic Kidney Disease: An Overlooked Syndrome?Journal of cachexia, sarcopenia and muscle · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lasin OzbekDepartment of Medicine, Koç University School of Medicine, Istanbul 34450, Turkey.ORCID 0000-0002-2828-555X
Sama Mahmoud Abdel-RahmanDepartment of Medicine, Koç University School of Medicine, Istanbul 34450, Turkey.ORCID 0009-0005-1980-7749
Selen UnluDepartment of Medicine, Koç University School of Medicine, Istanbul 34450, Turkey.
Mustafa GuldanDepartment of Medicine, Koç University School of Medicine, Istanbul 34450, Turkey.ORCID 0000-0002-0480-5370
Sidar CopurDepartment of Internal Medicine, Koç University School of Medicine, Istanbul 34450, Turkey.
Alexandru BurlacuFaculty of Medicine, University of Medicine and Pharmacy "Grigore T Popa", 700115 Iasi, Romania.ORCID 0000-0002-3424-1588
Adrian CovicFaculty of Medicine, University of Medicine and Pharmacy "Grigore T Popa", 700115 Iasi, Romania.ORCID 0000-0002-9985-2486
Mehmet KanbayDepartment of Medicine, Division of Nephrology, Koç University School of Medicine, Istanbul 34450, Turkey.ORCID 0000-0002-1297-0675

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity poses a significant and growing risk factor for chronic kidney disease (CKD), requiring comprehensive evaluation and management strategies. This review explores the intricate relationship between obesity and CKD, emphasizing the diverse phenotypes of obesity, including sarcopenic obesity and metabolically healthy versus unhealthy obesity, and their differential impact on kidney function. We discuss the epidemiological evidence linking elevated body mass index (BMI) with CKD risk while also addressing the paradoxical survival benefits observed in obese CKD patients. Various measures of obesity, such as BMI, waist circumference, and visceral fat assessment, are evaluated in the context of CKD progression and outcomes. Mechanistic insights into how obesity promotes renal dysfunction through lipid metabolism, inflammation, and altered renal hemodynamics are elucidated, underscoring the role of adipokines and the renin-angiotensin-aldosterone system. Furthermore, the review examines current strategies for assessing kidney function in obese individuals, including the strengths and limitations of filtration markers and predictive equations. The management of obesity and associated comorbidities like arterial hypertension, type 2 diabetes mellitus, and non-alcoholic fatty liver disease in CKD patients is discussed. Finally, gaps in the current literature and future research directions aimed at optimizing the management of obesity-related CKD are highlighted, emphasizing the need for personalized therapeutic approaches to mitigate the growing burden of this intertwined epidemic.

Indexed as

AdiposityObesityRenal Insufficiency, ChronicBody Mass IndexHumansPrognosisRisk Factorsglomerular filtration ratekidney functionobesitysarcopenic obesityvisceral adiposity

Identifiers

PMID39459455
PMCPMC11509396

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.